Gilead Sciences, headquartered in Foster City, California, employs 18,000 people and focuses on developing medicines for HIV, hepatitis, COVID-19, and cancer. Its portfolio includes numerous marketed products and several promising candidates.
GILD has been in the news recently: Trodelvy, developed by Gilead Sciences, and Merck's Keytruda have been shown to reduce the risk of aggressive breast cancer progression by 35%, with patients surviving an average of 16.5 months compared to 9.2 months on traditional chemotherapy. Additionally, Gilead Sciences has partnered with AONN+ to launch a grant program starting in July 2025, aimed at improving oncology navigation and patient outcomes with funding of up to $500,000.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
